More than 40 Clinical Studies Using Accuray Technology, including CyberKnife were presented at the European Society for Radiotherapy and Oncology also known as (ESTRO)
That new data presented at the meeting reinforces the benefits of the CyberKnife® System for the treatment of prostate cancer at multiple stages of the cancer journey.
The studies, shared at the annual congress held in Vienna, Austria, indicate the system’s accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body radiation therapy (SBRT), expanding access to a non-invasive, short course of care to more men.
At this year’s ESTRO meeting important analyses of real-world evidence (RWE) underscored the benefits of our unique robotic and helical platforms, reaffirming their use as patients’ primary care option or along with other modalities such as surgery, chemotherapy or immunotherapy.
Stand out studies focused on the CyberKnife System for the treatment of prostate cancer, building on a robust body of clinical data supporting its use and confirming the durability and quality of life after 10 years post-treatment.
“We’re grateful to the clinicians who continue to evaluate our technologies and advance personalized and precise care of patients through the work that they do,” said Suzanne Winter, president and CEO of Accuray.
During the meeting, Accuray hosted a symposium titled, “Integrating Advanced Techniques in Genitourinary Radiotherapy: Harmonizing Precision, Personalization, and Efficacy,” attended by 350 healthcare professionals. The event featured global thought leaders who spoke on advancements in the treatment of genitourinary indications – prostate, kidney, and bladder cancers – with radiotherapy.
Patient care in these areas is dynamic and evolving rapidly, with SBRT now recognized as a safe and effective alternative to conventional treatments for localized prostate cancer and evidence continuing to build for the use of SBRT in salvage prostate treatments.
CyberKnife Platform: Empowering Advances in Prostate Cancer Patient Care
A retrospective analysis titled, “Long-term outcomes and treatment efficacy in high-risk prostate cancer patients treated with stereotactic extreme hypofractionated radiotherapy,” reports on 262 men over the age of 70 or with severe comorbidities who were diagnosed with either non-metastatic high-risk or very high-risk prostate cancer and received SBRT delivered with the CyberKnife System in five sessions.
With a median follow-up of 39 months, investigators found that treatment with the system offers a promising option with favorable outcomes and low rates of acute and late urogenital (UG) and gastrointestinal (GI) toxicities.
Early results from a trial on stereotactic salvage radiotherapy for macroscopic prostate bed recurrence after prostatectomy: STARR (NCT05455736)” is a prospective study evaluating the use of stereotactic salvage radiotherapy (SSRT) delivered with the CyberKnife System in five sessions.
Androgen deprivation therapy was prohibited during SSRT. An early analysis of 51 patients with a median follow up of 16 months found that the CyberKnife System provides an effective and convenient option with mild toxicity for the treatment of recurrent cancer in the prostate bed following prostatectomy. The study investigators concluded, “Only mild toxicity was reported, underlining the safety of the treatment. Moreover, SSRT may be considered a convenient approach considering the shorter treatment duration if compared to standard approach.”
Prostate cancer is among the diseases we treat most often at the CyberKnife Center of Miami, and our vast experience allows us to take on the most difficult and complicated cases. That’s why many patients come from far and wide to be treated at our cancer center, traveling from across the world to CyberKnife Miami. Our reputation of effective, successful treatment, is as important as being known for getting patients treated as soon as possible, so they can get on with their lives.
Call us at 305-279-2900 to set up a consultation and see our cancer specialist in Miami, or with any questions you have about prostate cancer treatment with CyberKnife.